News Headlines

  1. TrialScope Welcomes Moderna Into Its Community Of Clinical Trial Sponsors 7/29/2020

    TrialScope announces the addition of Moderna to its growing customer roster. Reflecting its commitment to transparency, Moderna has selected the TrialScope Disclose™ platform to manage and automate its clinical trial disclosure process and maintain regulatory compliance.

  2. PCI Pharma Services Announces Global Expansion Of Clinical Trial Services 7/29/2020

    PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply- chain network into continental Europe to complement offerings available at its UK and Ireland sites. The COE is expected to be completed in January 2021.   

  3. Ciox Health Acquires Biomedical Natural Language Processing Pioneer, Medal, Inc. 7/29/2020

    Ciox Health, a leading health technology company, today announced its acquisition of San Francisco-based biomedical Natural Language Processing (biomed-NLP) technology company, Medal, Inc., a leader in the application of AI techniques to the interrogation of unstructured medical record data. The acquisition accelerates capabilities to enable real-world data (RWD) in support of research that advances patient care.

  4. Alcon Standardizes On Veeva Vault CDMS For Clinical Data Management 7/23/2020

    Modernizing systems enables expanded roles and responsibilities for data management organization.

  5. ERT Expands eCOA Solution For Higher Fidelity CNS Assessments 7/22/2020

    ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with the leading neuroscience technology company, Cogstate, Ltd. The collaboration enables ERT to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoint measurement to improve safety and efficacy assessment in clinical trials, including capabilities for at-home testing.

  6. Cognizant Shared Investigator Platform For Life Sciences Reaches Major Milestone In Accelerating Drug Discovery 7/21/2020

    Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries.

  7. Thermo Fisher Scientific And CSL Enter Strategic Partnership To Provide Best-In-Class Pharma Services 7/1/2020

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives.

  8. CluePoints Launches Powerful Business Intelligence Platform 6/25/2020

    CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced the launch of its new business intelligence platform, BEYOND. Designed to encompass more than just early risk detection, this extended visualization solution takes CluePoints beyond the interrogation of data and allows Sponsor and CRO users to explore areas of interest in one integrated business intelligence system.

  9. ERT Continues To Drive Innovation In Virtualization For Respiratory Clinical Trials 6/25/2020

    ERT, the global leader in clinical endpoints data collection, today announced a strategic partnership with Inofab Health, a healthcare technology company designing and developing ultrasonic spirometry technology for in-clinic and at-home use.

  10. Amylyx Pharmaceuticals Announces Completion Of Enrollment In The PEGASUS Trial Of AMX0035 In Alzheimer’s Disease 6/15/2020

    Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced it has completed enrollment in the Phase II PEGASUS trial assessing AMX0035 in individuals with Alzheimer’s disease.